BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27311748)

  • 1. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation.
    Liu J; Chang YJ; Yan CH; Xu LP; Jiang ZF; Zhang XH; Liu KY; Huang XJ
    J Infect; 2016 Sep; 73(3):261-70. PubMed ID: 27311748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
    Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
    Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
    Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential association of CMV-specific CD8+ T lymphocyte reconstitution with the risk of CMV reactivation and persistency in post allogeneic stem cell transplant patients.
    Shams El-Din AA; El-Desoukey NA; Amin Tawadrous DG; Fouad NMBE; Abdel-Mooti M; Hotar SF
    Hematology; 2018 Sep; 23(8):463-469. PubMed ID: 29313439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT.
    Pourgheysari B; Piper KP; McLarnon A; Arrazi J; Bruton R; Clark F; Cook M; Mahendra P; Craddock C; Moss PA
    Bone Marrow Transplant; 2009 Jun; 43(11):853-61. PubMed ID: 19104497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.
    Moins-Teisserenc H; Busson M; Scieux C; Bajzik V; Cayuela JM; Clave E; de Latour RP; Agbalika F; Ribaud P; Robin M; Rocha V; Gluckman E; Charron D; Socié G; Toubert A
    J Infect Dis; 2008 Sep; 198(6):818-26. PubMed ID: 18666855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
    Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
    Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
    Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
    Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
    Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
    Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients.
    Paouri B; Soldatou A; Petrakou E; Theodosaki M; Tsentidis C; Kaisari K; Oikonomopoulou C; Matsas M; Goussetis E
    Pediatr Transplant; 2018 Aug; 22(5):e13220. PubMed ID: 29777573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.
    Tey SK; Kennedy GA; Cromer D; Davenport MP; Walker S; Jones LI; Crough T; Durrant ST; Morton JA; Butler JP; Misra AK; Hill GR; Khanna R
    PLoS One; 2013; 8(10):e74744. PubMed ID: 24146744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT.
    Król L; Stuchlý J; Hubáček P; Keslová P; Sedláček P; Starý J; Hrušák O; Kalina T
    Bone Marrow Transplant; 2011 Aug; 46(8):1089-98. PubMed ID: 21057553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
    Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M
    J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
    Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
    Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.
    Horowitz A; Guethlein LA; Nemat-Gorgani N; Norman PJ; Cooley S; Miller JS; Parham P
    J Immunol; 2015 Nov; 195(9):4524-36. PubMed ID: 26416275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.